Back to News
Market Impact: 0.3
Akeso's Ivonescimab Received Priority Review In China For Biliary Tract Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
China’s NMPA granted Priority Review to Akeso’s ivonescimab, in combination with chemotherapy, for first-line treatment of locally advanced or metastatic biliary tract cancer. Priority Review is a regulatory milestone, not an approval; the article provides no financial figures or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- South Korea’s KOSPI halts trade after 8% wipeout on AI losses
- U.S. stock futures rise after AI rout batters Wall St; payrolls data in focus
- ’Our phones are exploding’: Goldman Sachs dissects historic Wall Street crash
- Top Democrats call to rein in AI buildout after midterms sweep: 'National data center moratorium now'